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Table 1. Clinical Data in 14 Patients 
Cardiac Preop Age at 
Pt. Age at Time Arrest Drugs Time of Op Postop Drugs Follow-Up Present 
No. of Study Initial Diagnosis 0rVF (no.) (mo.1 (no.1 (mo.) Treatment 
1 I mo. SVT t 3 I 3 42 0 
2 I5 mo. Wide QRS tachycardia t 5 I5 3 43 0 
3 13 mo. SVT. VT t 4 13 I 32 0 
4 1 mo. Near-miss SIDS - 2 N/A N/A 21 0 
5 24 mo. Tachycardia in utero + 5 24 0 25 0 
6 10 mo. Tachycardia in utero + 4 10 2 18 0 
7 36 mo. SVT 3 NlA NiA 17 Procainamide, 
tocainide 
8 30 mo. SVT, WPW 8 N/A NIA IS 0 
9 26 mo. SVT t 7 27 0 I? 0 
IO 54 mo. Head injury, SVT f 4 NIA N/A 13 0 
II 17 mo. SVT due IO WPW I 17 I 10 Encainide 
12 2 weeks SVT + 2 N/A N/A 5 0 
I3 I day Cardiomegaly, SVT. WPW f I N/A N/A 5 0 
I4 36 mo. VT + 3 N/A N/A 5 Flecainide 
N/A = not applicable; Op = operation; Postop = postoperative; Preop = preoperative: Pt. = patient: SIDS = sudden infant death syndrome: SVT = 
supraventricular tachycardia: VF = ventricular fibrillation: VT = ventricular tachycardia: WPW = Wolff-Parkinson-White syndrome: t = present; - = absent. 
bright signals, we imaged the heart of eight patients in an 
attempt to document the tachycardia focus. Images were 
obtained with use of a General Electric Sigma 1.5 tesla whole 
body magnet. Children were sedated with sodium secobar- 
bital (2 to 4 mg/kg body weight intravenously) before posi- 
tioning in the magnet. Both cardiac and respiratory gating 
were employed. T,- and Tz-weighted images were obtained 
in both the sagittal nd the transverse plane. 
methods. In each surgical patient epicardial 
mapping was carried out with two wires 0.5 cm apart sutured 
to the ventricular epicardium as a reference. A hand-held 
probe was used to map the ventricles during ventricular 
tachycardia and during sinus rhythm when possible. Map- 
ping was performed before cardiopulmonary b pass. En- 
docardial mapping was carried out on the two patients whose 
ventricle was opened uring cardiopulmonary bypass. Acti- 
vation times were measured manually on a strip chart 
recording and plotted on a map. The earliest point of 
activation was determined and a point with electrical ctivity 
earlier than the onset of the QRS complex of each of the 
three surface lectrocardiographic (ECG) leads was sought. 
Each patient had at least one cryolesion applied to the point 
of earliest activation. 
A nitrous oxide-controlled cryoprobe with a 3 mm tip was 
used with a thermocouple in the tip. Cryolesions of -70” to 
-79°C were created for 60 to 120 s. A visible ice ball was 
present for each lesion. 
symptoms. The patients could be divided into 
two groups on the basis of presenting symptoms: 1) inces- 
sant ventricular tachycardia with life symptoms 
(that is, cardiac arrest or severe or wo iac failure, 
or both), and 2) incessant ventricular tachycardia without 
life-threatening symptoms. 
Fourteen patients, eight giris and six b 
ventricular tachycardia. Their ages rang 
months). Nine of t 
transferred to our center after several unsuccessful attempts 
to control their arrhythmia. 
Nine qf the 14 palients were considered lo have life- 
threatening symptoms. One patient was classified as having 
a near-miss udden infant death syndrome (7). Eight were 
previously misdiagnosed ashaving supraventricular t chy- 
cardia, three of those as Wolff-Parkinson-White syndrome 
with antidromic tachycardia. Our review of the ECGs con- 
vinced us that no patient hab Wolff-Parkinson-White syn- 
drome. One patient was being treated with procainamide but 
had a syncopal spell necessitating hospitalization a d the 
remaining five patients were given digoxin intravenously 
with subsequent ventricular fibrillation (Table I). 
Noninvasive testing. ECC tracings at the time of presen- 
tation to our institution showed tachycardia r tes ranging 
from 132 to 300 beats/min (mean 232). Ventricular tachycar- 
dia was defined as a different QRS complex with a rate >200 
beatslmin or25% greater than the sinus rate. The duration of 
the QRS complex ranged from 90 to 212 ms (mean 127). Five 
patients had cardiomegaly, asevidenced by a chest radio- 
graphic ardiothoracic ratio >55%. Two-dimensional echo- 
cardiography was performed on each patient. Six patients 
had echocardiographic evidence of moderate to severely 
decreased ventricular function (shortening fraction ~32%) 
(7). with overall shortening fractions ranging from 8% to 43% 
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drug had been tried at other centers. Successful treatment 
was defined as complete abolition of ventricular tachycardia 
and couplets on repeated 24 h ambulatory ECG monitoring. 
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activation on the surface ECG, it was assumed that the focus 
was intramyocardial or endocardial. Brief periods of aortic 
cross clamping were used during cryothermia to increase the 
depth of the lesion. Approximately 1 cm’ of epicardium was 
cryoablated in this patient. No patient had a serious compli- 
cation or died. 
Follow-up. All I4 patients are alive and asymptomatic at 
a mean of 28 months of follow-up (range 12 to 53). Eleven 
patients are currently taking no medications; they were the 
earliest patients in our series. One patient continues to take 
two medications and the remaining two are taking one 
antiarrhythmic drug. Each patient has a normal cardiotho- 
racic ratio on chest radiography and a normal shortening 
fraction by echocardiography. No patient requires anticon- 
gestive medications and no patient has a pacemaker. 
The change in our treatment plan from requiring exci- 
sional surgery for incessant ventricular tachycardia in the 
very young to using drug therapy or a combination of drug 
therapy and cryoablative surgery resulted in no deaths in our 
series of 14 patients (5.8). an improvement over previous 
series (l-3). This change was allowed by the availability of 
type Ic drugs, amiodarone and combinations of these. Al- 
though type Ic drugs may lead to arrhythmic morbidity and 
mortality in adults with ischemic heart disease, this drug 
effect is less common in children (9) and it was not manifest 
in this series. There was no proarrhythmia or mortality in 
our series with postdrug electrophysiologic testing. Al- 
though in children amiodarone may lead to complications 
such as biochemical hyperthyroidism and liver enzyme 
elevations, no serious complications occurred in this or our 
other pediatric series (IO). After 12 to 18 months we fre- 
quently decreased the dose or gave the drug 5 days a week. 
In this way it was often possible to minimize the biochemical 
side effects. After 24 months it was frequently possible to 
co iscontinue amiodarone. 
management of ventricular tachycwdia. We 
propose the following medical management plan for neo- 
nates, infants and young children with ventricular tachycar- 
dia. If rapid control is necessary because of a rapid heart rate 
or congestive heart failure, I mg/kg intravenous procaina- 
mide every 3 to 5 min for I5 doses (total dosage 15 mg/kg 
over about I h) or until sinus rhythm occurs is often 
successful. Several of the patients in this series received 
more rapid infusions at other centers and suffered from 
hemodynamic collapse. Very careful monitoring of blood 
pressure is mandatory. Increasing the time between doses 
will often reverse small decreases in blood pressure. Colloid 
infusion may occasionally be necessary and is best con- 
trolled by direct measurement of central venous pressure. 
When initial control is achieved oral or nasogastric propran- 
olol, 1 mg/hg every 6 h, shoul 
discontinued. 
QrulJeccri~id~, 100 to 22s m&n’ body surface area, in 
two divided oral doses is given next (II). The dose of 
flecainide may be increased only once every 3 days. Seamy 
decainide concentrations sbo 
and 1.0 mg/ml. If the clinical ventricular tachyc 
completely abolished, an elect 
performed, as was done in eat 
there are no data to prove that lack ofar~~ythmia i 
will prevent chnical ~~oar~~ythrnia~ 
series. In a series of 23 patients in 
oral flecainide, no deaths o 
occurred when electrophysidogic study was used as a guide 
(I%). If severe depression of sinoatrial or atrioventrictdar 
(AV) node function is present or if ventricular tachycardia is 
inducible witk single. double or burst ventricular pacing, 
alternate therapy is needed. Encainide is 
less depressive effects on ventricular hem 
tion. Therefore, if the patient has moderate or se 
gestive heart failure. encainide may be substi 
flecainide at a dosage of 70 to I20 mg/m’ 
divided doses. If encainide is clinically 
charge electrophysiologic testing is man 
efficacy and to attempt to rule out severe 
AV node function and to rule out a proarrbythmic effect. 
* drug is incfictive, amiodarone should be 
nglkg per dqv for 10 days (IO). The mainte- 
nance dose is 5 mg/kg per day. If amiodarone alone is 
ineffective, a type Ic drug can be added. In this instance one 
half the usual dose of the type Ic drug is used. 
rf this pharmncologic regimen fails, surgery should be 
undcrtcrken. The drug treatment should probably be carried 
out in a center experienced in this type of surgery because 
decompensation may occur. 
I. When a patient is controlled by drug 
treatment, he or she should be followed up very closely. A 
transtelephonic monitor is sent home with the patient for 
both routine follow-up and emergency situations. Amio- 
darone requires close biochemical follow-up (IO). Although 
surgical treatment was beneficial in each of our seven 
patients in whom it was used, it was only immediately 
curative in two of the seven: each of the other five patients 
required additional drags. four of whom were subsequently 
weaned from all drug treatment, without recurrence. It is 
possible that epicardial cryothermia did not produce a trans- 
mural lesion. Brief periods of cross clamping of the aorta 
have been used to enforce the loss. 
In children it is possible that, if sudden death is pr;- 
vented, they may “grow 
parents were so informed. 
on ECG or ambulatory ECG monitoring I year later. drug 
weaning was initiated. The drug that was considered more 
toxic wds stopped first: after an appreciable length of time, 
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